Update on the hyper immunoglobulin M syndromes
- PMID: 20180797
- PMCID: PMC2855828
- DOI: 10.1111/j.1365-2141.2010.08077.x
Update on the hyper immunoglobulin M syndromes
Abstract
The Hyper-immunoglobulin M syndromes (HIGM) are a heterogeneous group of genetic disorders resulting in defects of immunoglobulin class switch recombination (CSR), with or without defects of somatic hypermutation (SHM). They can be classified as defects of signalling through CD40 causing both a humoral immunodeficiency and a susceptibility to opportunistic infections, or intrinsic defects in B cells of the mechanism of CSR resulting in a pure humoral immunodeficiency. A HIGM picture can also be seen as part of generalized defects of DNA repair and in antibody deficiency syndromes, such as common variable immunodeficiency. CD40 signalling defects may require corrective therapy with bone marrow transplantation. Gene therapy, a potential curative approach in the future, currently remains a distant prospect. Those with a defective CSR mechanism generally do well on immunoglobulin replacement therapy. Complications may include autoimmunity, lymphoid hyperplasia and, in some cases, a predisposition to lymphoid malignancy.
Figures
References
-
- Atkinson TP, Smith CA, Hsu YM, Garber E, Su L, Howard TH, Prchal JT, Everson MP, Cooper MD. Leukocyte transfusion-associated granulocyte responses in a patient with X-linked hyper-IgM syndrome. Journal of Clinical Immunology. 1998;18:430–439. - PubMed
-
- Benesch M, Pfleger A, Eber E, Orth U, Zach MS. Disseminated cytomegalovirus infection as initial manifestation of hyper-IgM syndrome in a 15-month-old boy. European Journal of Pediatrics. 2000;159:453–455. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
